ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) EPS (Basic): HK$-0.58 (TTM As of Dec. 2025)


HKSE:01541 ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
7 GF Score
Price HK$3.56
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) EPS (Basic)?

ImmuneOnco Biopharmaceuticals (Shanghai) HKSE:01541 -3.26% 7 EPS (Basic) is HK$-0.58 as of Dec. 2025. GuruFocus rates HKSE:01541 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

ImmuneOnco Biopharmaceuticals (Shanghai)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.58.

ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.58.

ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS without NRI for the six months ended in Dec. 2025 was HK$-0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.58.

During the past 3 years, the average EPS without NRI Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, ImmuneOnco Biopharmaceuticals (Shanghai)'s highest 3-Year average EPS without NRI Growth Rate was 29.10% per year. The lowest was 21.40% per year. And the median was 25.25% per year.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ImmuneOnco Biopharmaceuticals (Shanghai) EPS (Basic) Related Terms

ImmuneOnco Biopharmaceuticals (Shanghai) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) EPS (Basic) Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-2.41 -1.21 -1.15 -0.90 -0.59

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only -0.61 -0.47 -0.43 -0.40 -0.18
HKSE:01541
7GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc HKSE:01541
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-241.471-0)/412.437
=-0.59

ImmuneOnco Biopharmaceuticals (Shanghai)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-72.905-0)/417.566
=-0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.58 mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a EPS (Basic) of HK$-0.58 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS (Basic) too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current EPS (Basic) is HK$-0.58. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS (Basic) compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s EPS (Basic) of HK$-0.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current EPS (Basic) is HK$-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current EPS (Basic) of HK$-0.58. The current EPS (Basic) is HK$-0.58. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current EPS (Basic) is HK$-0.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
7GF Score

Get the complete analysis for HKSE:01541

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.56
Price